• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·France·Healthcare·SNY
Share

Sanofi Stocks

$ 43.55Last Updated 19.05.2026

Issuer Rating

7/7
Performance

Strong

Risk

Low

Recommendation

Buy

Market Cap

$ 104.86B

$ 43.55
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Latest news

06.02.2026 15:00

Agomab Therapeutics IPO: Pfizer and Sanofi-backed biotech starts trading

24.12.2025 16:58

Sanofi is expanding its vaccine business. It will buy Dynavax for $2.2 billion

15.12.2025 19:23

Sanofi's stock is down. Its sclerosis drug suffers 'double blow'

28.08.2025 19:20

Goldman and Citi expect the rally in European equities to continue despite the crisis in France

23.05.2025 14:48

Biotech small cap Vigil soars 240% on news of acquisition by pharma giant Sanofi

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Company Valuation

Undervalued
6/7

From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. In particular, the stock is underpriced on P/E, of fair value on EV/E

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of SNY is 57 and suggests 31% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

21.05.2026 21:45

Betting 50 years ahead: what analysts are saying about SpaceX's historic IPO

21.05.2026 21:13

Nebius to buy alternative energy source for data center. Shares soared 17%

21.05.2026 20:33

Oil is up more than 3%. Iran is preparing a system of fees for passage through Hormuz

21.05.2026 19:40

The White House will give $2 billion to quantum companies. Who is the main beneficiary?

21.05.2026 19:15

Trench instead of hype: will Burberry become the most interesting company in European luxury

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026